1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).
Eur J Med Chem 2020;
206:112686. [PMID:
32795773 DOI:
10.1016/j.ejmech.2020.112686]
[Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Accepted: 06/25/2020] [Indexed: 01/10/2023]
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA), as a classic reason for genuine skin and flimsy tissues diseases, is a worldwide general wellbeing risk and has already tormented humanity for a long history, creating a critical need for the development of new classes of antibacterials. 1,2,3-Triazole moiety, readily interact with diverse enzymes and receptors in organisms through weak bond interaction, is among the most common frameworks present in the bioactive molecules. 1,2,3-Triazole derivatives, especially 1,2,3-triazole-containing hybrids, possess broad-spectrum activity against a panel of clinically important bacteria including drug-resistant pathogens, so rational design of 1,2,3-triazole derivatives may open a door for the opportunities on the development of novel anti-MRSA agents. This review is an endeavour to highlight the current scenario of 1,2,3-triazole-containing hybrids with potential anti-MRSA activity, covering articles published between 2010 and 2020.
Collapse